iPSCs To Accelerate Cell and Gene Product Development

Whitepaper

Published: October 30, 2023

iPSCs To Accelerate Gene and Cell Product Development

Credit : Istock

Induced pluripotent stem cells (iPSCs) present the greatest revolution in medicine as a starting material for cell therapy and ex vivo gene therapy candidates.

Allogeneic iPSC generation is a complex process, requiring extensive technical expertise. In the current iPSC reprogramming landscape, researchers are faced with many issues, such as unreliable genomic stability and prolonged validation.

By outsourcing this step, researchers can benefit from high-quality iPSC products and services to efficiently develop and advance regenerative medicine and cell therapies.

These whitepapers highlight how optimized CRISPR protocols and site-specific knock-in technology can be used to engineer simple or complex genetic modifications in allogenic iPSCs.

Download these whitepaper's to discover:

Research and cGMP-grade cell products and tools
Robust research and development services
Research equivalent and cGMP manufacturing

Brought to you by

Access These Whitepapers for FREE Now!

Information you provide will be shared with the sponsors for this content. Technology Networks or its sponsors may contact you to offer you content or products based on your interest in this topic. You may opt-out at any time.